本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Aquestive Therapeutics Inc.

3.92
-0.0650-1.63%
成交量:72.35萬
成交額:287.65萬
市值:4.78億
市盈率:-5.00
高:4.12
開:4.07
低:3.91
收:3.98
52周最高:7.55
52周最低:2.12
股本:1.22億
流通股本:1.15億
量比:0.63
換手率:0.63%
股息:- -
股息率:- -
每股收益(TTM):-0.7836
每股收益(LYR):-0.7836
淨資產收益率:148.50%
總資產收益率:-33.92%
市淨率:-14.19
市盈率(LYR):-5.00

資料載入中...

公司資料

公司名字:
Aquestive Therapeutics Inc.
交易所:
NASDAQ
成立時間:
2004
員工人數:
147
公司地址:
30 Technology Drive,Warren,New Jersey,United States
郵編:
07059
電話:
傳真:
- -
簡介:
Aquestive Therapeutics, Inc.於2004年1月在特拉華州成立。該公司是一家通過創新遞送技術推進藥物的製藥企業,專註於開發侵入性標準療法的替代方案。它開發包括用於過敏性休克的腎上腺素前藥在內的專有候選藥物,並擁有由其工廠生產的授權商業化產品。

董事

名稱
職位
John Cochran
Vice Chairman of the Board
Keith J. Kendall
Chief Executive Officer, President and Director
Santo Costa
Chairman of the Board
James S. Scibetta
Director
Julie Krop
Director
Marco Taglietti
Director
Nancy Lurker
Director

股東

名稱
職位
Keith J. Kendall
Chief Executive Officer, President and Director
Daniel Barber
Senior Vice President - Chief Operating Officer
A. Ernest Toth, Jr.
Interim Chief Financial Officer
Gary H. Slatko
Senior Vice President - Chief Medical Officer
Ken Marshall
Senior Vice President - Chief Commercial Officer
Lori J. Braender
Senior Vice President - General Counsel, Chief Compliance Officer and Corporate Secretary
Peter Boyd
Senior Vice President - Business Process and Information Technology
Theresa Wood
Senior Vice President - Human Resources and Organizational Development
A. Mark Schobel
Chief Innovation and Technology Officer